Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a trial in elderly women with breast cancer, primary systemic (neoadjuvant) therapy with letrozole with or without low dose daily oral cyclophosphamide was shown to increase overall clinical response.

Metronomic Cyclophosphamide Adds Value to Neoadjuvant Hormonal Therapy for Elderly Breast Cancer Patients